Prognostic Value of Pre-treatment Naples Prognostic Score (NPS) in Patients with Osteosarcoma

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2020 Feb 1

PMID 32000789

Citations 21

Authors

QianKun Yang

Tong Chen

Zhongxiang Yao

Xiaojing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to evaluate the clinical significance of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.

Methods: The clinical data of 133 osteosarcoma patients between January 2011 and February 2018 in our hospital was retrospectively collected and analyzed. NPS was calculated from four parameters, including serum albumin level, serum total cholesterol (TC), lymphocyte-to-monocyte ratio (LMR), and neutrophil-to-lymphocyte ratio (NLR). Patients were divided into three groups (group 1-3) based on NPS. The relationships between NPS and clinical features, overall survival (OS), and progression-free survival (PFS) were analyzed. Two prediction models based on NPS and clinical parameters were developed: clinical parameters model (model A), and the combined model of NPS and clinical parameters (model B). Their predictive performances were further evaluated and compared.

Results: The median follow-up time of this cohort was 46.0 (range, 5-75) months, while the median OS and PFS was 40 (range, 5-75) months and 36 (range, 5-71) months, respectively. NPS was significantly correlated with gender, tumor location, Enneking stage, pathological fracture, local recurrence, and metastasis (all P < 0.05). Variables of NPS, Enneking stage, local recurrence, metastasis, and NLR were confirmed as independent prognostic factors for OS and PFS by univariate and multivariate Cox analysis. Prediction model B obtained larger AUCs for OS and PFS and showed better consistency between nomogram-predicted and actual survival than that of model A at the follow-up time of 1-, 3-, and 5-year.

Conclusions: NPS was a novel, reliable, and multidimensional prognostic scoring system with favorable predictive performance for patients with osteosarcoma.

Citing Articles

Associations of prognostic nutritional index with cardiovascular all-cause mortality among CVD patients with diabetes or prediabetes: evidence from the NHANES 2005-2018.

Xu W, Zhang L, Yang Q, Cao Y, Rao R, Lv L Front Immunol. 2025; 16:1518295.

PMID: 40013151 PMC: 11860081. DOI: 10.3389/fimmu.2025.1518295.

The role of neutrophils in osteosarcoma: insights from laboratory to clinic.

Xia M, Han Y, Sun L, Li D, Zhu C, Li D Front Immunol. 2024; 15:1490712.

PMID: 39582869 PMC: 11582048. DOI: 10.3389/fimmu.2024.1490712.

Predicting the prognosis of Wilms tumor by peripheral blood cells: a real-world study of more than 30 years.

Jie L, Qin-Lin S, Xiao-Mao T, Peng H, Zhuang-Cheng W, Zai-Hong H Ital J Pediatr. 2024; 50(1):245.

PMID: 39543678 PMC: 11566747. DOI: 10.1186/s13052-024-01805-8.

Clinical significance of the modified Naples prognostic score in patients with stage II-III colon cancer undergoing curative resection: a retrospective study from the real world.

Li X, Cheng C, Huo X, Zhao C, Yuan H, Chen G Front Oncol. 2024; 14:1403666.

PMID: 39351349 PMC: 11439623. DOI: 10.3389/fonc.2024.1403666.

Survival Predictors Before Preoperative Adjuvant Chemotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.

Hashimoto I, Kano K, Suematsu H, Yamada T, Watanabe H, Kanematsu K In Vivo. 2024; 38(2):881-889.

PMID: 38418152 PMC: 10905439. DOI: 10.21873/invivo.13514.

References

Tokunaga R, Sakamoto Y, Nakagawa S, Ohuchi M, Izumi D, Kosumi K . CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. Int J Colorectal Dis. 2016; 32(1):99-106. DOI: 10.1007/s00384-016-2668-5. View

Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Podzemny V . Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer. Dis Colon Rectum. 2017; 60(12):1273-1284. DOI: 10.1097/DCR.0000000000000961. View

de Martino M, Leitner C, Seemann C, Hofbauer S, Lucca I, Haitel A . Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC). BJU Int. 2014; 115(3):397-404. DOI: 10.1111/bju.12767. View

Cho J . Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res. 2007; 30(1):64-74. DOI: 10.1007/BF02977780. View

Gou B, Cao H, Cheng X, Shang W, Xu M, Qian W . Prognostic value of mean platelet volume to plateletcrit ratio in patients with osteosarcoma. Cancer Manag Res. 2019; 11:1615-1621. PMC: 6388949. DOI: 10.2147/CMAR.S193949. View

Vasquez L, Leon E, Beltran B, Maza I, Oscanoa M, Geronimo J . Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas. J Pediatr Hematol Oncol. 2017; 39(7):538-546. DOI: 10.1097/MPH.0000000000000911. View

Fritzsching B, Fellenberg J, Moskovszky L, Sapi Z, Krenacs T, Machado I . CD8/FOXP3-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology. 2015; 4(3):e990800. PMC: 4404826. DOI: 10.4161/2162402X.2014.990800. View

Jiang R, Yang Z, Luo D, Guo L, Sun R, Chen Q . Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. Med Oncol. 2014; 31(8):80. DOI: 10.1007/s12032-014-0080-y. View

Han X, Wang W, He J, Jiang L, Li X . Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett. 2019; 17(3):2592-2598. PMC: 6365895. DOI: 10.3892/ol.2019.9905. View

10.

Nie W, Zhao L, Guo R, Wang M, Ye F . Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma. Eur Rev Med Pharmacol Sci. 2018; 22(19):6239-6244. DOI: 10.26355/eurrev_201810_16030. View

11.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G . Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32(6):423-36. DOI: 10.1016/j.ctrv.2006.05.005. View

12.

Aggarwal B, Vijayalekshmi R, Sung B . Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009; 15(2):425-30. DOI: 10.1158/1078-0432.CCR-08-0149. View

13.

Bhatt V, Saleem A . Review: Drug-induced neutropenia--pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004; 34(2):131-7. View

14.

Li X, Tang H, Wang J, Xie X, Liu P, Kong Y . The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2016; 32:1-6. DOI: 10.1016/j.breast.2016.11.024. View

15.

Mandal C, Rahman M . Targeting Intracellular Cholesterol is a Novel Therapeutic Strategy for Cancer Treatment. J Cancer Sci Ther. 2015; 6(12):510-513. PMC: 4376010. DOI: 10.4172/1948-5956.1000316. View

16.

Buntzel J, Micke O, Kisters K, Buntzel J, Mucke R . Malnutrition and Survival - Bioimpedance Data in Head Neck Cancer Patients. In Vivo. 2019; 33(3):979-982. PMC: 6559905. DOI: 10.21873/invivo.11567. View

17.

Soderstrom L, Rosenblad A, Adolfsson E, Bergkvist L . Malnutrition is associated with increased mortality in older adults regardless of the cause of death. Br J Nutr. 2017; 117(4):532-540. DOI: 10.1017/S0007114517000435. View

18.

Xia W, Liu Z, Shen D, Lin Q, Su J, Mao W . Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World J Surg Oncol. 2016; 14:127. PMC: 4850668. DOI: 10.1186/s12957-016-0889-2. View

19.

Yi J, Wang D, Li Z, Hu J, Niu X, Liu X . C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review. PLoS One. 2014; 9(5):e94632. PMC: 4011684. DOI: 10.1371/journal.pone.0094632. View

20.

Machado I, Lopez-Guerrero J, Scotlandi K, Picci P, Llombart-Bosch A . Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Arch. 2018; 472(5):815-824. DOI: 10.1007/s00428-018-2316-2. View